MNKD MANNKIND CORP
FY2025 10-K
MANNKIND CORP (MNKD) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: biopharmaceutical company focused on inhalation drug delivery and proprietary pulmonary technologies
- • New emphasis: multiple amendments (up to seventh) to Commercial Supply Agreement with United Therapeutics Corporation in current year
Management Discussion & Analysis
- • No revenue or profitability data provided in the overview section
- • Cardiometabolic segment consists of Afrezza, Furoscix, V-Go device with recent acquisition of scPharma in Oct 2025
Risk Factors
- • Regulatory risk: Inflation Reduction Act of 2022 limited insulin copays to $35/month for Medicare Part D starting 2023, pressuring Afrezza pricing and reimbursement
- • Geopolitical risk: V-Go wholly manufactured in China, exposed to U.S.-China trade tensions and potential tariff changes affecting margins
Get deeper insights on MANNKIND CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.